Trial Profile
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2023
Price :
$35
*
At a glance
- Drugs Lumasiran (Primary)
- Indications Primary hyperoxaluria type 1
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 18 Mar 2023 Status changed from active, no longer recruiting to completed.
- 15 Aug 2022 Planned End Date changed from 1 Jun 2023 to 1 Jan 2023.
- 15 Aug 2022 Planned primary completion date changed from 1 Jun 2023 to 1 Jan 2023.